Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 13/20 | 0.73 |
| ▸ | NAALAD2 | Q9Y3Q0 | 6/20 | 0.72 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20073634 | 0.97 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20346417 | 0.97 | FOLH1 (0.73) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22618719 | 0.89 | FOLH1 (0.78) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL22618802 | 0.86 | FOLH1 (0.63) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL1377049 | 0.85 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18161468 | 0.85 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14102870 | 0.85 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12145776 | 0.85 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL14102890 | 0.85 | FOLH1 (1.00) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL25473411 | 0.85 | FOLH1 (0.57) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | CD47, MCL1, BCL9 | FOLH1 3142/4885NAALAD2 3364/4885RIMKLA 4043/4885 |
| US-20230028880-A1 | CD38-BINDING AGENTS AND USES THEREOF | CD38, CD47, CD2 | FOLH1 2116/4885NAALAD2 275/4885RIMKLA 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.